Overview
NICE is unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy because no evidence submission was received from Boehringer Ingelheim.
Last reviewed: 24 May 2017
Next review: We will review this decision if the company decides to make a submission.